Continuing Education Activity
Female fertility decreases with advancing age due primarily to progressive reductions in both the quantity and quality of oocytes, beginning with a finite supply established before birth and declining over time through atresia. This activity provides clinicians with an evidence-based overview of age-related fertility decline and its growing relevance in modern reproductive health. The higher rates of chromosomal abnormalities, miscarriage, and pregnancy complications, and the critical role of counseling regarding reproductive aging, fertility expectations, and available diagnostic and management strategies as more individuals delay childbearing and maternal age increases, are also discussed.
Participants in this activity will gain an understanding of the pathophysiology of reproductive aging, clinical evaluation of diminished ovarian reserve, and the role of biomarkers, eg, anti-Müllerian hormone (AMH). The activity also reviews appropriate timing for infertility evaluation, referral to reproductive endocrinology specialists, and counseling regarding fertility preservation, assisted reproductive technologies, and patient-centered family planning decisions. This activity for healthcare professionals is designed to enhance the learner's competence in evaluating and educating patients about age-related fertility decline, emphasizing proactive patient education, treatment options, monitoring parameters to provide evidence-based and patient-centered care, and implementing an appropriate interprofessional approach when managing this critical aspect of family planning.
Objectives:
Identify key physiologic mechanisms contributing to age-related fertility decline.
Determine the appropriate timing for infertility evaluation in women aged 35 years or older.
Communicate evidence-based counseling to patients regarding age-related fertility decline issues.
Coordinate management strategies with interprofessional team members to improve care coordination and outcomes in patients with age-related processes affecting the decline in fertility.
Access free multiple choice questions on this topic.
Introduction
The capacity to produce a child, known as fertility, declines with age. This age-related fertility decline results from reduced quality and quantity of oocytes.[1][2] Females are born with a finite number of oocytes.[3] In contrast to their male counterparts, females most likely do not create new gametes throughout their lifetime. The number of oocytes peaks in utero at around 20 weeks of gestation and subsequently declines steadily until approximately age 32. At this age, the number of oocytes decreases at a greater rate until age 37, after which oocyte numbers drop even more rapidly.[4]
As females focus more on careers and other life goals, the initial childbearing age is being pushed back. Among women older than 30, the number of first births increased 6-fold between 1970 and 2002. The number of women aged 30 to 34 years delivering their first child rose by 28% between 2000 and 2014; the number of women aged 35 or older rose by 23%.[5] Accordingly, age-related fertility decline complications have been increasing among our population, and fecundability has decreased. Therefore, patient counseling and education on age-related fertility decline is a critical aspect of family planning. Clinicians have an essential role in educating patients about their potential fecundity from an early age and promptly referring patients for further workup when indicated.[6] Natural fertility tends to be overestimated, and delayed childbearing is often overlooked as a risk for infertility.
The American Society for Reproductive Medicine (ASRM) describes infertility as the inability to achieve a successful pregnancy, based on an assessment of an individual’s medical, sexual, and reproductive history, among other relevant factors, such that medical intervention is necessary to facilitate conception. Clinicians should have a solid working knowledge of the general trend of age-related fertility decline so that appropriate counseling can be undertaken with patients before they reach the point of decreased or even irreversible loss of fertility.
Testing women for decreased ovarian reserve may be recommended in women aged 35 years and older attempting conception without success after 6 months. This age parameter may be lowered for women with diminished ovarian reserve risk factors (eg, having only 1 ovary, a history of ovarian surgery, exposure to chemotherapy or radiation, and unexplained infertility). In any patient aged 40 or older seeking infertility care, recommending evaluation by a reproductive endocrinologist is appropriate. Management primarily involves discussing the decreasing pregnancy rates for patients in their 30s and 40s, natural and assisted reproductive options, and shared decision-making as a part of routine family planning counseling.
Etiology
As women age, fertility declines. In earlier times, a 35-year-old pregnant woman would be a rarity; however, currently, women aged 35 years and older conceiving their first or second child are common. The decline in fertility is a modern problem seen throughout the world, which is not always easily solved by assisted reproductive technology.[3] The age-related fertility decline stems from several factors. However, the primary underlying cause is the decline in oocyte quantity and quality with advancing age. Other factors include an increased risk of pregnancy complications, miscarriage, changes in the ovulatory cycle, exposure to environmental toxins, and a potential decline in uterine health.[7]
The number of gametes in the ovary decreases through the process of atresia, with an initial decline from the maximum number of approximately 6 to 7 million gametes around 20 weeks of gestation to approximately 1 to 2 million oocytes at birth, to 300,000 to 500,000 at puberty, to 25,000 at age 37, and around 1,000 at age 51. The average age of menopause in the United States is 51.[4] Methods to slow or reverse this decline in gametes during perimenopause have not been identified. While the exact mechanism is unknown, oocyte atresia is believed to be related to changes in circulating hormones, specifically rising levels of follicle-stimulating hormone paired with declining levels of AMH and inhibin B. Additionally, the quality of oocytes declines with age.[4]
A high-quality oocyte is critical for successful fertility. Gamete quality is closely tied to gamete genetics, which is more frequently adversely affected in women with increasing age than in men. In mothers younger than 25 years, the rate of Down syndrome is around 2%. However, in women aged 35 or older, that risk jumps to almost 35%. As a person ages, the risk of chromosomal abnormalities, specifically aneuploidy, increases.[8] Aneuploidy occurs when an incorrect number of chromosomes is present in a germ cell. The presence of such aneuploidy dramatically affects oocyte quality.
This, in turn, affects fertility, as the presence of aneuploidy is a common cause of early miscarriage and one of the most common causes of infertility.[9] Aneuploidy can be attributed to 65% to 75% of early failed pregnancies and approximately 35% of clinically recognized miscarriages. Aneuploidy risk increases 10 times after the maternal age of 40 compared to a maternal age younger than 25. The occurrence of aneuploidy is primarily attributed to meiotic nondisjunction caused by changes in the meiotic spindle, but little is known about how to correct this process. Age is clearly related.[10]
Epidemiology
While the ability to conceive is not the same across all populations and can vary due to many factors, patterns of predicted infertility have been established. Studies have analyzed the average age of infertility in many countries. In a Japanese study, the highest fertility rates were in women aged 24 or younger. Their fertility decreased with age, a pattern consistent with data from a similar study of European women.[11]
Fertility decreases with age, but other contributing factors are likely present. Sexual activity tends to decline with age. Furthermore, tubal disease, leiomyomas, endometriosis, tubal and ovarian surgeries, and chemotherapy may also play into the decrease in fertility seen with aging.[4] Because fertility can be linked to many factors, determining the exact prevalence of age-related causes is difficult. However, based on data from multiple trials of both insemination and in vitro fertilization, the chances of conception, both naturally and via artificial reproductive technology, decrease with age. As many as 10% to 15% of all couples attempting conception have reported difficulties with fertility.[12][13]
Pathophysiology
The pathophysiology of age-related fertility decline in females is multifactorial. A decrease in the number of gametes and the integrity of those gametes is affected by age due to oocyte atresia over time and changes in the meiotic spindle, which can lead to aneuploidy. Other contributing factors include changes in ovulation patterns with age, aging of the uterus, and increasing risks of complications.[7] The mechanisms underlying decreased fertility are poorly understood but are most likely genetically encoded on the X chromosome and autosomes.[4] Age-related alterations in granulosa cells can impair oocyte quality, reduce follicular support, and ultimately contribute to reduced fertility, especially among women of advanced maternal age.[14] Physiologic factors that can diminish oocyte quantity and quality include the following:
DNA damage
Genetic mutations
Cohesion deterioration and chromosome missegregation
Meiotic recombination errors
Spindle assembly checkpoint
Telomere shortening
Mitochondrial dysfunction
Ovarian fibrosis and inflammation
[15]
Endometrial dysfunction also plays a significant role in age-related reproductive decline. Optimizing endometrial health is therefore important, as aging is associated with progressive deterioration in endometrial function and receptivity. Mitochondrial dysfunction appears to be a key contributor to this process, acting as a central driver of cellular aging. Irreversible mitochondrial damage may lead to endometrial senescence, which in turn may contribute to the gradual decline in reproductive potential and implantation receptivity.[16]
History and Physical
No specific history or physical examination findings suggest declining fertility, except for age. Menstrual irregularities (eg, abnormal uterine bleeding and oligomenorrhea) may not necessarily be present in a patient with decreasing fertility but are often associated with perimenopausal and postmenopausal transitions. However, laboratory and ultrasound examinations can be useful in evaluating fertility issues.[3]
Evaluation
Testing women for decreased ovarian reserve with antral follicle count, AMH levels, ultrasound, and hysterosalpingogram may be recommended in women aged 35 and older attempting conception without success after 6 months.[8] This age parameter may be lowered for women with diminished ovarian reserve risk factors (eg, having only 1 ovary, a history of ovarian surgery, exposure to chemotherapy or radiation, and unexplained infertility). In any patient aged 40 and older seeking infertility care, recommending evaluation by a reproductive endocrinologist is appropriate.[17]
Clinicians should be aware that while tests for ovarian reserve may indicate the number of gametes a woman has left, these values do not reflect oocyte quality.[17] Testing for ovarian reserve can predict a patient’s potential response to gonadotropin stimulation. Patients with decreased ovarian reserve have been shown to have less likelihood of pregnancy success with assisted reproductive technology. Currently, the preferred biomarker for evaluating patients is AMH, which has been shown to correlate with the number of available oocytes.[18]
AMH is secreted from the ovary, specifically from the granulosa cells. Currently, no direct measure of the remaining ovarian primordial follicles is available, but AMH is a marker of functional ovarian reserve. Beginning at age 25, AMH levels start to decrease with increasing age. However, significant variation in AMH levels has been noted between similarly aged women due to ethnicity and other contributing factors. Furthermore, AMH levels can vary by 20.7% depending on the timing within the menstrual cycle. This, plus the lack of an international standard and inter-assay variations, are limitations that may hamper the clinical utility of AMH levels in an individual patient.[19]
Treatment / Management
Obstetric and gynecology clinicians are essential as patient educators and links to reproductive endocrinology specialists. Patient counseling should include general ways to optimize fertility, including maintaining a healthy weight and upholding a healthy lifestyle, including smoking cessation and reduction of alcohol intake.[5] Obstetric and gynecology clinicians should educate patients regarding fertility concerns and family planning, regardless of the patient's current desire to actively achieve pregnancy. Clinicians should discuss the decreasing pregnancy rates for patients in their 30s and 40s, both naturally and using assisted reproductive technology, as part of routine counseling about family planning.[20]
Various techniques for fertility preservation with cryopreservation of oocytes or embryos are now available worldwide. "Age-banking" is now used for oocyte preservation to avoid age-related infertility. With ovarian stimulation followed by the vitrification of 15 oocytes, a woman younger than 35 has an 85.2% probability of a live birth. Banking of ovarian tissue is another option, although more invasive. Oocyte cryopreservation remains the best option currently for women who want to preserve fertility due to concerns about age-related decline in fertility. Embryo cryopreservation is a less ideal option because, if the couple subsequently separates, ownership disputes can arise.[21]
Although most couples prefer to have a child with genetic material from both parents if possible, oocyte donation may be the best option for some couples. Because aneuploidy rates increase with increasing age, in vitro fertilization with a woman older than 42 has an 85% risk of aneuploidy. Similarly, a woman aged 35 needs about 5 oocytes to get a euploid embryo, whereas a woman older than 42 would need 200 oocytes. Decreased responsiveness to ovarian stimulation is also seen in older women. With donor oocyte use, in vitro fertilization success depends on the donor's age. Reproductive endocrinologists discuss this option with patients who have not previously undergone oocyte cryopreservation, as donor oocytes have a high likelihood of a good clinical outcome.[22]
Differential Diagnosis
The differential diagnosis of age-related infertility includes many other causes of infertility. Although infertility can be attributed to a myriad of causes, the 3 main components include ovulatory factor, tubal factor, and male factor.[23] Environmental factors, sexual dysfunction, genetic abnormalities, premature ovarian insufficiency, and unexplained infertility are all included in the differential diagnosis of age-related decline in fertility.
The following factors have the potential to decrease fertility:
Prognosis
While age-related fertility decline has no actual cure, patients who are promptly evaluated and referred to a reproductive endocrinologist have multiple options available to them for treatment. This is important, as patients with infertility can be emotionally affected by their diagnosis. Prompt evaluation and referral to a specialist is the best thing that an obstetric and gynecologic clinician can do for patients of advancing age who are seeking fertility.
Furthermore, another factor to consider is that assisted reproductive technology can be prohibitively expensive for patients, as insurance often does not cover the cost.[24] By talking over family planning and options for fertility preservation at routine well-woman examinations when women are younger, an opportunity to delay childbearing without as much concern about age-related infertility decline may be discussed and implemented based on shared decision-making.
Complications
Potential complications of age-related fertility decline include a true inability to conceive. The cost of utilizing assisted reproductive technology, as well as the low success rates for older women, are additional complications to keep in mind. Women who give birth at age 34 or older have increased rates of miscarriage, preterm birth, and congenital malformations, especially after the age of 40. Once pregnancy is achieved, complications, eg, gestational hypertension, preeclampsia, and gestational diabetes, are risks that are increased during pregnancy.
Consultations
Prompt evaluation and referral to a specialist is the best thing that an obstetric and gynecologic clinician can do for patients of advancing age who are seeking fertility.
Deterrence and Patient Education
The obstetric and gynecologic generalist plays a vital role as a patient counselor during annual well-woman exams. This counseling should include general ways to optimize fertility, eg, maintaining a healthy weight and adopting a healthy lifestyle, including smoking cessation and reducing alcohol intake.[5] Each appointment offers an opportunity for the physician to inform the patient about fertility, regardless of the patient’s current desire to achieve pregnancy actively. Cultural factors of the 21st century have led women to not only have fewer children but also begin procreating much later than women of prior generations. Once infertility is established as a diagnosis, the treatment options are not often available to everyone due to high costs and the lack of insurance.[24]
Many women have little knowledge overall about age-related fertility decline. They may falsely believe that they have control over their fertility. Clinicians also tend to be unaware and have limited resources for patients. There is a general overconfidence regarding the success of assisted reproductive technologies as women age. Despite the recognized need, few instruments and interventional studies are available on age-related fertility decline.[25] Educational interventions should thus include information about age-related declines in fertility in both men and women. Donated eggs and sperm may be required for assisted reproduction techniques in women at older ages. Any patients who desire children should be counseled regarding reproductive educational matters.[25]
Pearls and Other Issues
Age-related fertility decline is primarily driven by reductions in both the number and quality of oocytes, with a more rapid decline beginning in the mid-30s and accelerating after age 40, largely due to increased aneuploidy. Endometrial and uterine changes may also contribute, as aging is associated with declining endometrial receptivity and cellular senescence, which may be related to mitochondrial dysfunction. Early counseling about reproductive aging and timely evaluation are important, particularly for individuals attempting conception at age 35 or older. A common pitfall is overreliance on ovarian reserve testing to predict natural fertility, as these measures better reflect oocyte quantity than quality. Although reproductive aging cannot be prevented, education about fertility timelines, consideration of fertility preservation (eg, oocyte cryopreservation), and optimization of general health may help mitigate its impact.
Enhancing Healthcare Team Outcomes
Age-related fertility decline results from progressive reductions in both the quantity and quality of oocytes. Females are born with a finite number of oocytes that peak during fetal development and gradually decline through atresia. Oocyte loss accelerates after the early 30s and becomes more rapid after age 37. Aging also affects oocyte quality, increasing rates of chromosomal abnormalities such as aneuploidy, which contributes to infertility, early pregnancy loss, and congenital anomalies. Evaluation focuses on clinical history, risk assessment, and ovarian reserve testing, including anti-Müllerian hormone levels and antral follicle count, particularly in individuals aged 35 and older who have not conceived after 6 months of attempts. Management includes counseling regarding fertility expectations, lifestyle optimization, and consideration of assisted reproductive technologies or fertility preservation strategies.
Interprofessional collaboration strengthens early identification and management of age-related fertility decline. Physicians, primarily obstetrician-gynecologists and reproductive endocrinologists, lead diagnostic evaluation and treatment planning, while primary care clinicians and advanced practitioners provide initial counseling, risk assessment, and timely referral. Nurses support patient education, care coordination, and monitoring during evaluation or treatment. Pharmacists review medications that may affect fertility and assist with medication management during assisted reproductive therapies. Coordinated communication among team members promotes shared decision-making, appropriate use of diagnostic testing, and timely referral to fertility specialists. Such collaboration improves patient-centered care, reduces delays in infertility evaluation, and supports informed reproductive planning.
References
- 1.
ACOG Committee Statement No. 22: Anticipatory Counseling Regarding Ovarian-Factor Fertility Decline.
Obstet Gynecol. 2025 Nov 01;146(5):e98-e104. [
PubMed: 41100882]
- 2.
Li S, Tang M, Zhu S, Zhang Z, Cao Y, Xue R. SIRT3 attenuates AGEs-induced senescence in human granulosa cells through enhancing mitophagy.
Cell Biol Toxicol. 2026 Jan 13;42(1):20. [
PMC free article: PMC12835053] [
PubMed: 41530572]
- 3.
Baird DT, Collins J, Egozcue J, Evers LH, Gianaroli L, Leridon H, Sunde A, Templeton A, Van Steirteghem A, Cohen J, Crosignani PG, Devroey P, Diedrich K, Fauser BC, Fraser L, Glasier A, Liebaers I, Mautone G, Penney G, Tarlatzis B., ESHRE Capri Workshop Group. Fertility and ageing.
Hum Reprod Update. 2005 May-Jun;11(3):261-76. [
PubMed: 15831503]
- 4.
American College of Obstetricians and Gynecologists Committee on Gynecologic Practice and Practice Committee. Female age-related fertility decline. Committee Opinion No. 589.
Fertil Steril. 2014 Mar;101(3):633-4. [
PubMed: 24559617]
- 5.
Quinn MM, Cedars MI. Declining Fertility with Reproductive Aging: How to Protect Your Patient's Fertility by Knowing the Milestones.
Obstet Gynecol Clin North Am. 2018 Dec;45(4):575-583. [
PubMed: 30401543]
- 6.
Crawford NM, Steiner AZ. Age-related infertility.
Obstet Gynecol Clin North Am. 2015 Mar;42(1):15-25. [
PubMed: 25681837]
- 7.
Rowe T. Fertility and a woman's age.
J Reprod Med. 2006 Mar;51(3):157-63. [
PubMed: 16674009]
- 8.
Madjunkov M, Madjunkova S, Librach C. The biology and clinical aspects of female infertility.
Syst Biol Reprod Med. 2026 Dec;72(1):23-54. [
PubMed: 41528185]
- 9.
Mikwar M, MacFarlane AJ, Marchetti F. Mechanisms of oocyte aneuploidy associated with advanced maternal age.
Mutat Res Rev Mutat Res. 2020 Jul-Sep;785:108320. [
PubMed: 32800274]
- 10.
Sánchez-Pavón E, Mendoza H, García-Ferreyra J. Trisomy 21 and Assisted Reproductive Technologies: A review.
JBRA Assist Reprod. 2022 Jan 17;26(1):129-141. [
PMC free article: PMC8769184] [
PubMed: 34542250]
- 11.
Konishi S, Kariya F, Hamasaki K, Takayasu L, Ohtsuki H. Fecundability and Sterility by Age: Estimates Using Time to Pregnancy Data of Japanese Couples Trying to Conceive Their First Child with and without Fertility Treatment.
Int J Environ Res Public Health. 2021 May 20;18(10) [
PMC free article: PMC8161326] [
PubMed: 34065492]
- 12.
Chu KY, Patel P, Ramasamy R. Consideration of gender differences in infertility evaluation.
Curr Opin Urol. 2019 May;29(3):267-271. [
PubMed: 30720494]
- 13.
Tamrakar SR, Bastakoti R. Determinants of Infertility in Couples.
J Nepal Health Res Counc. 2019 Apr 28;17(1):85-89. [
PubMed: 31110383]
- 14.
Wang H. The role of granulosa cells in oocyte development and aging: Mechanisms and therapeutic opportunities.
Semin Cell Dev Biol. 2025 Jul;171:103614. [
PubMed: 40300217]
- 15.
Park SU, Walsh L, Berkowitz KM. Mechanisms of ovarian aging.
Reproduction. 2021 Jul 14;162(2):R19-R33. [
PMC free article: PMC9354567] [
PubMed: 33999842]
- 16.
Kobayashi H, Nishio M, Umetani M, Shigetomi H, Imanaka S, Hashimoto H. Endometrial Aging and Reproductive Decline: The Central Role of Mitochondrial Dysfunction.
Int J Mol Sci. 2025 May 24;26(11) [
PMC free article: PMC12154470] [
PubMed: 40507871]
- 17.
Tal R, Seifer DB. Ovarian reserve testing: a user's guide.
Am J Obstet Gynecol. 2017 Aug;217(2):129-140. [
PubMed: 28235465]
- 18.
Lliberos C, Liew SH, Zareie P, La Gruta NL, Mansell A, Hutt K. Evaluation of inflammation and follicle depletion during ovarian ageing in mice.
Sci Rep. 2021 Jan 11;11(1):278. [
PMC free article: PMC7801638] [
PubMed: 33432051]
- 19.
Moolhuijsen LME, Visser JA. Anti-Müllerian Hormone and Ovarian Reserve: Update on Assessing Ovarian Function.
J Clin Endocrinol Metab. 2020 Nov 01;105(11):3361-73. [
PMC free article: PMC7486884] [
PubMed: 32770239]
- 20.
Liu K, Case A., REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY COMMITTEE. Advanced reproductive age and fertility.
J Obstet Gynaecol Can. 2011 Nov;33(11):1165-1175. [
PubMed: 22082792]
- 21.
Henry L, Labied S, Jouan C, Nisolle M. Preservation of female fertility: The current therapeutic strategy.
Int J Gynaecol Obstet. 2022 Jan;156(1):3-9. [
PubMed: 33829509]
- 22.
Makhijani R, Grow DR. Donor egg is the best second choice for many infertile couples: real progress in overcoming age-related fertility is not here yet.
J Assist Reprod Genet. 2020 Jul;37(7):1589-1591. [
PMC free article: PMC7376777] [
PubMed: 32654104]
- 23.
Carson SA, Kallen AN. Diagnosis and Management of Infertility: A Review.
JAMA. 2021 Jul 06;326(1):65-76. [
PMC free article: PMC9302705] [
PubMed: 34228062]
- 24.
Forti G, Krausz C. Clinical review 100: Evaluation and treatment of the infertile couple.
J Clin Endocrinol Metab. 1998 Dec;83(12):4177-88. [
PubMed: 9851748]
- 25.
García D, Rodríguez A, Vassena R. Actions to increase knowledge about age-related fertility decline in women.
Eur J Contracept Reprod Health Care. 2018 Oct;23(5):371-378. [
PubMed: 30354690]
Disclosure: Karen Carlson declares no relevant financial relationships with ineligible companies.
Disclosure: Paul Sparzak declares no relevant financial relationships with ineligible companies.
